Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068756 · ClinicalTrials.gov registry record · Phase 1
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01068756 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 14 participants.
The verdict
NCT01068756, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin
Interventions
- DRUG Rifampin
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068756
The ClinicalTrials.gov registry entry for NCT01068756 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT01068756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01068756 about?
NCT01068756 is a clinical study titled "Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects". The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin
What is the current status of trial NCT01068756?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-03. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01068756?
The interventions under investigation include: Rifampin (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01068756?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.